AAVB-081

· AAVantgarde Bio Srl

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AAVB-081, covering 2025-05-02 to 2025-05-02. Get the full timeline:

Most recent: Clinical Trial Update: Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa [Phase 1, Phase 2]

See pricing